Short answer: yes, for many people. Ketamine is one of the fastest-acting treatments available for depression. In controlled trials, 55–64% of people with treatment-resistant depression responded to ketamine, often within 24 hours to a few weeks. Results last longest with a series of sessions rather than a single dose, and when the experience is paired with ongoing psychotherapy.
Below is what the research shows on ketamine and Spravato success rates for depression, suicidal thoughts, PTSD, anxiety and alcohol use. We’ve also covered how long results last and who is a good candidate. Every figure names its source, and the full list is at the bottom of the page.
Considering ketamine-assisted therapy in Denver? Our psychiatric nurse practitioner screens every client for safety, and dosing sessions take place at our Greenwood Village office. Afterward, you work through the experience with your own therapist.
Book a free consultation or call (720) 504-4329.
Ketamine therapy success rates at a glance
- 64% responded within 24 hours. In a two-site randomized trial of people with treatment-resistant depression, 64% responded to a single ketamine infusion at 24 hours, compared with 28% given an active placebo (Murrough et al., 2013).
- Ketamine held its own against ECT. In a 403-patient trial published in the New England Journal of Medicine, 55.4% of patients responded to ketamine and 41.2% responded to electroconvulsive therapy. Ketamine was also easier on memory (Anand et al., 2023).
- Spravato roughly doubled remission in some trials. In the TRANSFORM-2 trial, 52.5% of people taking esketamine (Spravato) with an antidepressant reached remission at four weeks, compared with 31.0% taking an antidepressant with a placebo spray.
- Staying on treatment prevents relapse. Among people whose depression went into stable remission on Spravato, continuing treatment cut the risk of relapse by 51% (Daly et al., 2019).
- Suicidal thoughts dropped within a day. A meta-analysis of 167 people with suicidal ideation found a single ketamine dose reduced suicidal thoughts within one day, with effects lasting up to a week (Wilkinson et al., 2018).
- 67% of people with chronic PTSD responded. In a randomized trial of six ketamine infusions over two weeks, 67% of participants responded, compared with 20% on an active placebo (Feder et al., 2021).
- Real-world results look similar. In a study of 1,247 people treated with ketamine-assisted therapy at home, 62.8% had at least a 50% improvement in depression and 62.9% in anxiety after four sessions (Hull et al., 2022).
Ketamine, Spravato and ketamine-assisted psychotherapy: what’s the difference?
The research above covers three related but different treatments. Knowing which one a study tested helps you read the numbers.
- IV ketamine infusions: ketamine given through an IV, usually twice a week for a few weeks, at an infusion clinic. Most of the early depression research uses this form.
- Spravato (esketamine): an FDA-approved nasal spray for treatment-resistant depression. It’s given only at certified clinics, and patients stay for at least two hours of monitoring after each dose. In January 2025, the FDA approved it for use on its own, without a daily oral antidepressant (Johnson & Johnson).
- Ketamine-assisted psychotherapy (KAP): ketamine sessions paired with psychotherapy before and after, so the shift in perspective ketamine opens up gets put to use. This is what we offer at My Denver Therapy. Learn more about ketamine-assisted psychotherapy in Denver.
How well does ketamine work for depression?
Depression is where the evidence is deepest. Most studies focus on treatment-resistant depression, meaning depression that hasn’t improved after at least two antidepressants.
The first dose often works fast
- In the Murrough trial, depression scores in the ketamine group dropped from about 32 to about 16 within 24 hours of one infusion.
- By day seven, the difference from placebo was no longer statistically significant (MDedge). One dose rarely holds on its own.
A full course works better
- Ketamine vs. ECT: in ELEKT-D, patients received ketamine twice a week for three weeks. 55.4% responded, and 32.3% reached remission, compared with 20% for ECT (Psychiatric News).
- Spravato with an antidepressant: 52.5% reached remission after four weeks of twice-weekly dosing in TRANSFORM-2, compared with 31.0% on an antidepressant alone.
- Spravato alone: in the trial behind the 2025 FDA approval, 22.5% of patients reached remission at week four on Spravato alone, compared with 7.6% on placebo (PharmExec).
- A slow start isn’t a dead end: in a pooled analysis of the TRANSFORM trials, 54.9% of people who hadn’t responded by day two did respond by day 28 (Journal of Clinical Psychiatry).
Results can last with maintenance
In the SUSTAIN-1 trial, people who had responded to Spravato either kept taking it or switched to a placebo spray. Among those in stable remission, 26.7% who stayed on Spravato relapsed, compared with 45.3% who stopped. Among those with a stable response, 25.8% relapsed on Spravato and 57.6% relapsed after stopping (Daly et al., 2019).
The takeaway: ketamine is a strong start, and keeping the gains takes a plan. That plan can be maintenance sessions, ongoing therapy, or both.
Does ketamine help with suicidal thoughts?
Ketamine is one of very few treatments shown to reduce suicidal thoughts within hours.
- The 2018 meta-analysis found a significant drop in suicidal ideation within one day of a single infusion, lasting up to one week.
- The effect held even after adjusting for overall mood changes, which suggests ketamine may act on suicidal thinking somewhat independently of depression.
- In the at-home study, 62% of patients who reported suicidal ideation before treatment no longer reported it after four sessions (HMP Global summary).
Researchers are clear that more work is needed on long-term suicide risk, and ketamine is never a substitute for crisis care.
If you are thinking about suicide or are worried about someone, call or text 988 to reach the Suicide & Crisis Lifeline, available 24/7. If you are in immediate danger, call 911.
Does ketamine therapy work for PTSD and trauma?
- Chronic PTSD: in the Mount Sinai trial led by Adriana Feder, participants had lived with PTSD for a median of 14 years. After six infusions over two weeks, 67% responded, compared with 20% on an active placebo (Brain & Behavior Research Foundation).
- How long it lasted: responders stayed improved for a median of 27.5 days after the infusions ended.
- Complex trauma: in a study of ketamine-assisted psychotherapy across three private practices, patients with complex PTSD or developmental trauma showed some of the largest improvements in depression and anxiety (Dore et al., 2019).
The Feder team named their next step: pairing repeated ketamine with trauma-focused psychotherapy to make the response last. That pairing is the model we use. See our trauma therapy and PTSD therapy pages for the therapy side of that work.
Does ketamine therapy work for anxiety?
- In the 1,247-patient at-home study, 62.9% of patients had at least a 50% drop in anxiety scores, and 31.3% reached remission after four sessions.
- Fewer than 1% got worse on the anxiety measure (Hull et al., 2022).
- The Dore study of three ketamine-assisted psychotherapy practices found KAP decreased both depression and anxiety, especially in patients with severe symptoms.
Anxiety research on ketamine is younger than the depression research, and most of it isn’t placebo-controlled yet. The early numbers are encouraging, and the right fit depends on your history.
Why pairing ketamine with therapy matters
The best evidence for combining ketamine with psychotherapy comes from addiction research. In the KARE trial, people with severe alcohol use disorder received three ketamine infusions or placebo, combined with either relapse-prevention therapy or alcohol education.
- The ketamine-plus-therapy group stayed completely abstinent on 162 of 180 days, or 87% of days, over six months. That was the best result of any group (University of Exeter).
- The researchers concluded the findings point to a benefit of adding psychological therapy alongside ketamine (Grabski et al., 2022).
The same logic shows up across the depression and PTSD research. Ketamine opens a window of flexibility, and therapy is what turns that window into lasting change.
Wondering if you’re a candidate? A free consultation is the easiest way to find out. We’ll talk through your history, what you’ve already tried and whether ketamine-assisted therapy is a safe fit.
Book a free consultation or call (720) 504-4329.
Who is a good candidate for ketamine therapy?
Ketamine tends to be considered for people who:
- Have depression that hasn’t improved enough on two or more antidepressants
- Have PTSD or complex trauma and feel stuck in standard therapy
- Have persistent anxiety alongside depression
- Want a treatment that can work in days or weeks rather than months
Ketamine isn’t safe for everyone. A prescriber needs to screen for things like a history of psychosis or mania, heart and blood pressure problems, hyperthyroidism, and substance use. That screening is part of how we start every ketamine client.
Side effects and safety
- During the session: dissociation (feeling detached or dreamlike), dizziness, nausea, sedation and a temporary rise in blood pressure are the most common effects. They usually fade within a couple of hours.
- Monitoring: Spravato requires at least two hours of observation after each dose at a certified clinic.
- Misuse risk: ketamine is a controlled substance with potential for misuse, which is why medical screening and supervised dosing matter.
- Real-world tolerability: in the at-home study, fewer than 5% of patients reported side effects and six left treatment early because of side effects or adverse events (Consultant360).
Ketamine-assisted therapy at My Denver Therapy
The research points to a clear pattern: careful screening, a series of sessions, and real psychotherapy around the medicine. That’s how our program is built.
- In-house prescriber. Shannon Keane, our psychiatric nurse practitioner, evaluates every client and prescribes. If you already have an outside prescriber, we can coordinate with them.
- Supervised sessions in Greenwood Village. Dosing sessions take place at our Greenwood Village office and usually last two to three hours.
- Integration with your own therapist. You process each session in your regular therapy, at any of our offices or online.
- Early adopters. We were founding members of Journey Clinical’s ketamine-assisted therapy community.
- Clear costs. We’re out of network, and insurers generally don’t cover ketamine-assisted therapy. See current pricing on our ketamine-assisted psychotherapy page.
Comparing options? Read our guide to at-home ketamine therapy vs. in-office KAP, see how ketamine fits with medication management, or book a free consultation to talk it through.
Looking for more data? Browse our full therapy research and statistics hub.
Frequently asked questions
What is the success rate of ketamine therapy?
In controlled trials of treatment-resistant depression, 55–64% of people respond to ketamine. Remission rates run lower, roughly 30–50% depending on the study and how many sessions people receive. Real-world ketamine-assisted therapy programs report similar numbers: about 63% of patients improved by at least half after four sessions in one study of 1,247 people.
What is the Spravato success rate?
In the TRANSFORM-2 trial, 52.5% of people taking Spravato with an oral antidepressant reached remission at four weeks, compared with 31.0% on an antidepressant alone. In the trial behind its 2025 approval as a standalone treatment, 22.5% reached remission at four weeks on Spravato alone, compared with 7.6% on placebo.
How long does it take for ketamine or Spravato to work?
Many people notice a change within 24 hours of their first session. Others respond more gradually. In the Spravato trials, more than half of people who hadn’t improved by day two had responded by day 28, so a full course of treatment matters.
How long do ketamine results last?
The effect of a single dose usually fades within about a week. A series of sessions lasts longer. PTSD responders in one trial stayed improved for a median of about four weeks after their last infusion, and continued Spravato cut relapse risk by about half. Ongoing psychotherapy helps hold the gains.
How many ketamine sessions will I need?
Most research protocols use six to eight sessions over two to four weeks. That might be twice-weekly infusions for three weeks, or twice-weekly Spravato for four weeks. Ketamine-assisted psychotherapy plans are individualized, and your prescriber and therapist will set a schedule based on how you respond.
Is ketamine therapy covered by insurance?
Spravato is a brand-name medication that many insurance plans cover for treatment-resistant depression, often with prior authorization. Ketamine-assisted psychotherapy generally isn’t covered. My Denver Therapy is out of network, and we can walk you through costs at your free consultation.
Sources
- Anand, A., Mathew, S. J., Sanacora, G., et al. (2023). Ketamine versus ECT for nonpsychotic treatment-resistant major depression. New England Journal of Medicine, 388(25), 2315–2325.
- Daly, E. J., Trivedi, M. H., Janik, A., et al. (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression. JAMA Psychiatry, 76(9), 893–903.
- Dore, J., Turnipseed, B., Dwyer, S., et al. (2019). Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Journal of Psychoactive Drugs, 51(2), 189–198.
- Feder, A., Costi, S., Rutter, S. B., et al. (2021). A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. American Journal of Psychiatry, 178(2), 193–202.
- Grabski, M., McAndrew, A., Lawn, W., et al. (2022). Adjunctive ketamine with relapse prevention–based psychological therapy in the treatment of alcohol use disorder. American Journal of Psychiatry, 179(2), 152–162.
- Hull, T. D., Malgaroli, M., Gazzaley, A., et al. (2022). At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression. Journal of Affective Disorders, 314, 59–67.
- Murrough, J. W., Iosifescu, D. V., Chang, L. C., et al. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. American Journal of Psychiatry, 170(10), 1134–1142.
- Popova, V., Daly, E. J., Trivedi, M., et al. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression (TRANSFORM-2). American Journal of Psychiatry, 176, 428–438.
- Wilkinson, S. T., Ballard, E. D., Bloch, M. H., et al. (2018). The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. American Journal of Psychiatry, 175(2), 150–158.
- Johnson & Johnson. (2025). SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression.
This page summarizes published research for educational purposes and isn’t medical advice. Talk with a qualified prescriber about whether ketamine is right for you.





